UP Oncolytics' Zika Virus Therapy Shows Promise in Glioblastoma Preclinical Studies
Event summary
- UP Oncolytics presented preclinical data on its Zika virus-based glioblastoma therapy at the AACR Special Conference on Brain Cancer (March 23–25, 2026).
- Two studies demonstrated the therapy's ability to predict treatment response and induce tumor regression in glioblastoma models.
- The research was supported by Rosalind Franklin University's research centers and an Illinois Innovation Voucher Program award.
The big picture
Glioblastoma remains one of the most treatment-resistant cancers, with no new FDA approvals in two decades. UP Oncolytics' approach leverages the Zika virus's natural tropism for neural cells, potentially offering a targeted therapy where others have failed. The company's progress could signal a new wave of oncolytic virus therapies for brain cancers, though significant regulatory and clinical hurdles remain.
What we're watching
- Clinical Translation
- The pace at which UP Oncolytics advances from preclinical to clinical trials will determine the therapy's commercial viability.
- Regulatory Pathway
- Whether the FDA will accept the novel Zika virus approach given the lack of recent glioblastoma approvals.
- Competitive Landscape
- How this therapy differentiates from other oncolytic virus treatments in development for glioblastoma.
Related topics